EN DE
Watch BEVERLY JCG LTD. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BEVERLY JCG LTD. (9QX) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of BEVERLY JCG LTD. stock S$0.00, price S$0.00, that is 10.0% below the price, quality 47 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG

BJ BEVERLY JCG LTD. logo Thin data Nov 16, 2026

BEVERLY JCG LTD.

9QX · SG

Expensive (fair value 10% below the price) and falling price, but company just good enough: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Quality 47/100 
Loss over the last twelve months · -4.4% net margin (TTM) · fiscal year 2025 0.5% 
Revenue last quarter 29% below a year ago. 
Changed on Nov 5: S$0.0036 → S$0.0027 
Fair value 0.0027 SGD · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 3y −3.6 %/yr in SGD) 
Negative free cash flow 
Trails peers (1/10) 
Narrow moat 10/100 · thin data
Thin data 
⚠ Dilution⚠ Thinly traded
Watch BEVERLY JCG LTD. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.1000 SGD 0.0030 SGD Fair Value 0.0027 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 0.0030 SGD – 0.1000 SGD · the 0.0030 SGD price screens above the 0.0027 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow BEVERLY JCG in your weekly email

Every Wednesday you see whether BEVERLY JCG is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beverly Wilshire Ltd., an investment holding company, engages in the trading and distribution, and medical businesses in Singapore and Malaysia. The company operates through three segments: Trading and Distribution; Aesthetic Medical and Healthcare; and Investment and Others.

Show moreShow less

The Trading and Distribution segment engages in the trading and distribution of steel raw materials, consumables, instruments, and semi-finished products for steel mills, iron and steel foundries, and aluminum smelters in the Asia-Pacific region, as well as provision of ancillary services.

The Aesthetic Medical segment offers aesthetic medical services, including the provision of aesthetic medical, beauty, and wellness services. The Investment and Others segment provides management services, as well as marketing, distribution, and related services.

The company provides plastic surgery, cosmetic and reconstructive surgery, aesthetic dental care, cosmetological and aesthetical related treatments, hair transplant, physiotherapy, spa, and reflexology services; healthy aging therapy, health screening and wellness, and medical research services; and operates medical specialist center with outpatient and day care services and activities.

It also offers clinical and other general medical services, and beauty salons. The company was formerly known as Beverly JCG Ltd. and changed its name to Beverly Wilshire Ltd. in September 2025. Beverly Wilshire Ltd. was founded in 1987 and is headquartered in Singapore.

Stock analysis

BEVERLY JCG LTD. (9QX) currently trades at 0.0030 SGD, while our model-based Fair Value estimate is 0.0027 SGD, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the data coverage at low.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

BEVERLY JCG LTD. reported revenue of 9.4M SGD in FY2025 versus 9.0M SGD in FY2021, a compound +1.2%/yr. Reported net income was 46.0K SGD in FY2025.

Key figures

Market cap 3.6M SGD (≈ $2.8M) Micro · P/S ratio 0.60 · Net margin 0.5% · Return on equity −198% · Return on assets (EBIT) −41.1% (5-year average) · Operating margin −7.3% · Revenue (TTM) 8.0M SGD · Revenue growth (YoY) −28.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 75% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −10%, 9QX screens richer than that median.

Fair Value models

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings n/a 0.0100 SGD 0.0100 SGD 74
All 1 models by family
DCF Models
Owner Earnings n/a 0.0100 SGD 0.0100 SGD 74

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 53
How much profit the company makes from its sales and capital
Quality Growth 78
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 32
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+59.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−94.0% (2020) → −3.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

9QX screens overvalued: fair value 10% below the price. Compare with HCA Healthcare, Inc →

Compare BEVERLY JCG LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −10.0% · Below median
Profitability
Return on assets 1.2% · Below median
Net margin (12 months) −6.4% · Bottom 25%
Operating margin (12 months) −7.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −28.6% · Bottom 25%
Balance sheet
Debt / equity 0.41× · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 3.49× · Pricier than median
P/S (12 months) 0.65× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)20 · sector 34
FUTURE (revenue growth)0 · sector 33
PAST (return on equity)0 · sector 32
HEALTH (low debt)80 · sector 90
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs 9QX
DaVita Inc DVA $174.56 $218.90 +25% vs 9QX
Aier Eye Hospital Group 300015 ¥8.99 ¥10.88 +21% vs 9QX
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs 9QX
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs 9QX
The Ensign Group ENSG $188.41 $140.09 −26% vs 9QX
Encompass Health Corporation EHC $140.99 $94.81 −33% vs 9QX
Fresenius SE FRE €53.86 €34.77 −35% vs 9QX
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,771 ₹5,234 −40% vs 9QX
Dr. Sulaiman Al Habib Medical Services Group 4013 211.40 SAR 109.45 SAR −48% vs 9QX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BEVERLY JCG LTD.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BEVERLY JCG LTD. Fair Value". https://www.fairvalue-calculator.com/stock/9QX

Frequently asked questions

Is BEVERLY JCG LTD. (9QX) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of 0.0027 SGD versus a price of 0.0030 SGD, about 10% lower (overvalued).
What is the fair value of 9QX?
Our model-based fair value for BEVERLY JCG LTD. is 0.0027 SGD (as of Nov 16, 2026), built from audited fundamentals. The current price: 0.0030 SGD.
What is the quality score of 9QX?
BEVERLY JCG LTD. has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BEVERLY JCG LTD. (9QX)?
Our model-based price target is the fair value of 0.0027 SGD (as of Nov 16, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the BEVERLY JCG LTD. stock forecast for 2026?
Our models put fair value at 0.0027 SGD, about 10% lower versus a price of 0.0030 SGD (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of BEVERLY JCG LTD. (9QX)?
BEVERLY JCG LTD. reported trailing-twelve-month revenue of about 8.0M SGD (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of BEVERLY JCG LTD. (9QX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BEVERLY JCG LTD. it is 0.0027 SGD per share (as of Nov 16, 2026), against a price of 0.0030 SGD. It is the blended result of 1 valuation models in 1 family (DCF Models).
Is BEVERLY JCG LTD. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 9QX trades above its calculated fair value: price 0.0030 SGD, fair value 0.0027 SGD, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9QX?
No. The price is what the market pays today (0.0030 SGD); the fair value is what the company's own numbers justify (0.0027 SGD). For BEVERLY JCG LTD. the two are 0.0003 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is BEVERLY JCG LTD. worth?
The market values BEVERLY JCG LTD. at about 3.6M SGD (market capitalisation, as of Nov 16, 2026). Per share that is 0.0030 SGD; our models calculate a fair value of 0.0027 SGD per share.
How solid is the balance sheet of BEVERLY JCG LTD. (9QX)?
Balance-sheet figures for BEVERLY JCG LTD. (as of Nov 16, 2026): return on equity −197.9%, debt of 0.41 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 9QX from its 52-week high?
BEVERLY JCG LTD. trades at 0.0030 SGD, about 75% below its 52-week high of 0.0120 SGD and at the low of 0.0030 SGD (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0027 SGD is for.
Which stocks are comparable to BEVERLY JCG LTD.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BEVERLY JCG LTD. stock attractive at the current price?
The data as of Nov 16, 2026: price 0.0030 SGD, calculated fair value 0.0027 SGD (−10%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9QX calculated?
We run BEVERLY JCG LTD. through 1 models from 1 family: DCF Models. Every model gets the same audited fundamentals; the fair value of 0.0027 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. BEVERLY JCG LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BEVERLY JCG LTD. (9QX)?
The closing price on Nov 13, 2026 was 0.0030 SGD. Our model-based fair value is 0.0027 SGD, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BEVERLY JCG LTD. right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of BEVERLY JCG LTD.

How large is the market capitalisation of BEVERLY JCG LTD. (9QX)?
The market capitalisation of BEVERLY JCG LTD. is 3.6M SGD (≈ $2.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BEVERLY JCG LTD. (9QX)?
The price-to-sales ratio of BEVERLY JCG LTD. is 0.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of BEVERLY JCG LTD. (9QX)?
The net margin of BEVERLY JCG LTD. is 0.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BEVERLY JCG LTD. (9QX)?
The return on equity (ROE) of BEVERLY JCG LTD. is −198% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BEVERLY JCG LTD. (9QX)?
On an EBIT basis the return on assets of BEVERLY JCG LTD. is −41.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BEVERLY JCG LTD. (9QX)?
The operating margin of BEVERLY JCG LTD. is −7.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BEVERLY JCG LTD. (9QX)?
Revenue at BEVERLY JCG LTD. is down 28.6% versus a year earlier (3y avg −3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BEVERLY JCG LTD. (9QX) generate?
The free cash flow of BEVERLY JCG LTD. is −1.2M SGD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BEVERLY JCG LTD. (9QX) carry?
The net debt of BEVERLY JCG LTD. is 798K SGD (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch BEVERLY JCG LTD. in the live analysis

One click puts BEVERLY JCG LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.